Effect of Lutetium-177 Dota Octreotate Peptide Receptor Radionuclide Therapy in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome Refractory to Somatostatin Analogues

被引：0
|
作者：
Koffas, Apostolos
Popat, Rickin
Demetriou, George
Quigley, Ann-Marie
Navalkissoor, Shaunak
Caplin, Martyn
Toumpanakis, Christos
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)30774-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1059
引用
收藏
页码：S208 / S208
页数：1
相关论文
共 50 条
  • [1] Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
    Koffas, A.
    Popat, R.
    Dimitriou, G.
    Quigley, A. M.
    Navalkissoor, S.
    Caplin, M.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2016, 103 : 81 - 81
  • [2] Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues
    Ratnayake, G. M.
    Koffas, A.
    Theocharopoulos, I
    Hayes, A.
    Navalkissoor, S.
    Gnanasegaran, G.
    Quigley, A. M.
    Khoo, B.
    Mandair, D.
    Grossman, A.
    Caplin, M.
    Alsadik, S.
    Clark, R.
    Toumpanakis, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 157 - 157
  • [3] Lutetium-177 Dotatate peptide receptor radionuclide therapy outcomes for neuroendocrine tumours
    AlHilali, M.
    Carberry, J.
    Challis, A.
    Atherton, P.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1095 - S1096
  • [4] 177Lutetium-DOTA-octreotate therapy in progressive somatostatin receptor-expressing neuroendocrine neoplasms
    Delpassand, E.
    Mohammadali, H.
    Thamake, S.
    Broline, S.
    Ranganathan, D.
    Wagh, N.
    Tworowska, I.
    Delpassand, A.
    Puentes, J.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [5] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA Octreotate for Somatostatin Receptor-expressing Neuroendocrine Tumors: The First US Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Erion, Jack
    Somone, Jim
    Wolfangel, Robert
    Wolin, Edward M.
    Espenan, Gregory D.
    PANCREAS, 2013, 42 (02) : 373 - 373
  • [6] Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment
    Hamiditabar, Mohammadali
    Ali, Muzammil
    Roys, Joseph
    Wolin, Edward M.
    O'Dorisio, Thomas M.
    Ranganathan, David
    Tworowska, Izabela
    Strosberg, Jonathan R.
    Delpassand, Ebrahim S.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 436 - 443
  • [7] CONTROL NETS: CAPECITABINE ON TEMOZOLOMIDE RADIONUCLIDE THERAPY OCTREOTATE LUTETIUM-177 NEUROENDOCRINE TUMOURS STUDY
    Sjoquist, Katrin M.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 76 - 76
  • [8] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [9] Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumors of the small intestine
    Sabet, A.
    Dautzenberg, K.
    Haslerud, T.
    Aouf, A.
    Sabet, A.
    Simon, B.
    Mayer, K.
    Biersack, H.
    Ezziddin, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S211 - S211
  • [10] Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm
    Bober, Barbara
    Saracyn, Marek
    Lubas, Arkadiusz
    Kolodziej, Maciej
    Brodowska-Kania, Dorota
    Kapusta, Waldemar
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2022, 25 (01) : 54 - 61
12345